Essential medicines are those that satisfy the priority health-care needs of a population. In the formulation used by the World Health Organization (WHO), they are selected with regard to disease prevalence and public-health relevance, evidence of efficacy and safety, and comparative cost-effectiveness. They are intended to be available within functioning health systems at all times, in adequate quantities, in appropriate dosage forms, with assured quality and adequate information, and at prices that individuals and communities can afford.
The concept is both clinical and institutional. It identifies medicines with particularly important uses, but also provides a framework for organizing purchasing, financing, prescribing, distribution, and regulation. An essential medicines list is therefore more than an inventory: it connects decisions about which treatments matter most with the practical arrangements required to make them accessible. Its importance extends from primary health care to specialist services, including treatment for infectious diseases, cardiovascular conditions, mental disorders, and cancer.
The WHO Model List of Essential Medicines, first published in 1977, serves as a guide for national and institutional lists rather than a universally binding catalogue. Countries adapt it to their disease patterns, resources, and service capacities. Essential status does not establish that a medicine is appropriate for every patient, guarantee its availability, or replace regulatory authorization and clinical assessment.
Origins and development of the concept
Essential medicines policy emerged from a longstanding problem in health care: the existence of effective treatments did not ensure that populations could obtain them. Pharmaceutical markets offered growing numbers of products, while many health services lacked dependable supplies of comparatively inexpensive treatments. Limited purchasing budgets, fragmented distribution, and prescribing influenced by commercial promotion contributed to this mismatch. Selection of a manageable group of medicines offered a way to concentrate scarce organizational and financial resources.
In 1975, the World Health Assembly adopted resolution WHA28.66, which supported the development of national pharmaceutical policies and work on the selection and procurement of essential drugs. WHO convened an expert committee in 1977, producing the first Model List, with 208 medicines. The list established a practical precedent: a health system could identify priority treatments through a structured process rather than simply reproduce all products available on its market. It was conceived as adaptable guidance, not as a requirement that every country purchase precisely the same medicines.
The 1978 Declaration of Alma-Ata subsequently included the provision of essential drugs among the essential elements of primary health care. This linked pharmaceutical access to a wider programme encompassing prevention, maternal and child health, sanitation, nutrition, and treatment of common diseases. Medicines were not treated as an isolated commodity; their usefulness depended on trained personnel, accessible facilities, and coordinated services.
The scope of selection changed as treatment possibilities and disease burdens evolved. Early lists were strongly associated with basic services and relatively inexpensive, established products. Later editions increasingly addressed complex conditions and treatments requiring specialist infrastructure. The addition of antiretroviral medicines in 2002 was particularly significant: it demonstrated that high price alone need not prevent a medicine from being considered essential when its clinical and public-health importance was substantial. Expanded cancer listings and direct-acting treatments for hepatitis C in 2015 further illustrated this development.
WHO introduced a separate Model List of Essential Medicines for Children in 2007, recognizing that inclusion of an adult medicine does not ensure availability of an appropriate pediatric formulation. In 2017, it introduced the Access, Watch, Reserve classification of antibiotics within the essential medicines framework. Across these changes, the central distinction remained stable: essentiality concerns priority health needs and comparative therapeutic value, whereas implementation concerns how health systems translate those priorities into access.
Selection criteria and assessment of evidence
Selection begins with the health problems a population needs to address. Epidemiology helps establish their frequency, distribution, severity, and preventable consequences. A medicine for a common condition may have large population benefits even if its effect for each treated person is moderate. A treatment for a less common but life-threatening condition may also warrant priority. Essentiality therefore cannot be reduced to a ranking by prevalence or sales volume.
Clinical assessment examines whether a medicine produces meaningful benefits and whether those benefits justify its harms. Evidence from a randomized controlled trial, systematic reviews, and other appropriate research is evaluated in relation to available alternatives. Outcomes such as survival, functional ability, symptoms, and quality of life generally have more direct relevance than an isolated change in a laboratory measurement. A surrogate endpoint may support a decision, but its relationship to patient benefit requires scrutiny. Rare adverse effects and long-term safety may become clearer only after widespread use.
Comparative assessment is central. A new medicine may work better than no treatment yet offer little advantage over an established medicine already on a list. Selection committees consequently consider the size and certainty of incremental benefit, adverse effects, dosing complexity, interactions, and feasibility of use. An oral preparation, for example, may have operational advantages over an injectable medicine if both provide comparable outcomes for the same indication. Conversely, an injectable formulation may be indispensable when rapid action or inability to swallow makes oral treatment unsuitable.
Cost-effectiveness analysis considers resources used in relation to health outcomes achieved. Its scope can include the medicine, diagnostic testing, administration, monitoring, and management of adverse effects. Measures such as the quality-adjusted life-year or disability-adjusted life-year can help compare interventions, although results depend on assumptions, local prices, and the population studied. A medicine can be cost-effective yet have a large total budget impact if many people are eligible. Cost-effectiveness and affordability are therefore related but distinct questions.
Feasibility also shapes selection. A treatment requiring a specific diagnostic test, reliable refrigeration, or close laboratory monitoring cannot be assessed independently of those requirements. WHO expert committees consider applications through a documented process that includes evidence review and opportunities for public comment. Listings can be restricted to particular indications or formulations, and medicines can be removed when evidence or treatment standards change. This makes an essential medicines list a revisable expression of evidence-based medicine, rather than a permanent declaration that a product is valuable under every circumstance.
Organization of lists and therapeutic coverage
The WHO Model List organizes medicines into therapeutic and service-related sections, including anesthetics, anti-infective medicines, cardiovascular treatments, reproductive health products, and medicines for mental and neurological disorders. Entries commonly specify a medicine’s international nonproprietary name, dosage form, and strength. Such details matter: the availability of a tablet does not establish the availability of a pediatric oral liquid, and an injectable formulation may serve a different clinical purpose from an oral one.
The list distinguishes core and complementary medicines. The core list presents minimum medicine needs for a basic health-care system, emphasizing efficacious, safe, and cost-effective treatments for priority conditions. The complementary list covers priority diseases for which specialized diagnostic or monitoring facilities, specialist care, or specialist training may be needed. In some cases, consistently higher costs or less attractive cost-effectiveness also influence complementary placement. This distinction does not mean that complementary medicines are optional in every country or that they have inferior clinical value.
Selected entries carry a square-box symbol indicating that other medicines within the same pharmacological class may offer similar clinical performance. The accompanying qualifications determine whether alternatives are explicitly limited. This device allows national selection committees to choose an appropriate representative based on comparative evidence, availability, prices, and local practice. It does not authorize unrestricted substitution between all members of a class, nor does it establish dose equivalence between different products.
Coverage extends across prevention, treatment, and symptom relief. Vaccines prevent disease; oral rehydration therapy addresses fluid and electrolyte losses from diarrheal illness; and medicines such as metformin support long-term management of diabetes. Morphine has an established role in relief of severe pain and in palliative care. Specialist treatments, including certain monoclonal antibodies, show that essential medicines are not confined to old, chemically simple, or inexpensive products.
Children require particular attention because absorption, distribution, metabolism, dosing, and acceptable formulations change with development. The children’s list is intended for children up to 12 years of age and identifies age-appropriate medicines and preparations. Dispersible tablets can sometimes improve storage and transport compared with liquids while providing a usable pediatric formulation. Inclusion of a substance on an adult list, however, cannot establish its safety or suitable dosing for every pediatric age group. Similar specificity applies to medicines used during pregnancy, neonatal care, and other situations in which formulation and clinical context materially affect benefit and risk.
National adaptation and links to health coverage
The WHO Model List is advisory. National governments and health institutions develop their own lists through selection processes that reflect local needs and responsibilities. Relevant considerations include disease burden, treatment guidelines, regulatory status, available expertise, service organization, and financing. A country with substantial malaria transmission has different pharmaceutical priorities from one where malaria occurs mainly among travelers. Differences in antimicrobial resistance, age structure, and the prevalence of noncommunicable diseases also affect selection.
National lists frequently connect medicines to levels of care. Treatments that can be delivered safely through community or primary-care services may have broad distribution, while medicines requiring specialist supervision are assigned to referral facilities. This arrangement can support continuity if referral and supply systems function properly. It can also create access barriers when patients must travel long distances for treatment or monitoring. The designation of a service level therefore has practical implications beyond the medicine’s pharmacology.
An essential medicines list is distinct from a formulary, a treatment guideline, and a reimbursement schedule, although these documents often overlap. A formulary supplies information about selected medicines and their use. Clinical guidelines describe management pathways for particular conditions. Reimbursement rules determine which products or services a financing scheme pays for and under what conditions. A medicine can appear on a national essential medicines list without being fully reimbursed, or be reimbursed for only specified indications. Consistency among these instruments helps prevent contradictory purchasing and prescribing decisions.
Essential medicines are closely connected to universal health coverage because access to a consultation without access to treatment provides incomplete protection. Health financing arrangements determine whether costs are prepaid and pooled or paid directly by households at the point of use. Repeated purchases for hypertension, diabetes, or other chronic conditions can impose a continuing burden even when individual prescriptions are inexpensive. An entitlement to medicines is consequently meaningful only when funding, supply, and dispensing arrangements can deliver the covered treatment.
National adaptation also involves governance. Committees may include clinicians, pharmacists, public-health specialists, economists, and other relevant expertise. Published criteria, declared conflicts of interest, documented reasons for decisions, and scheduled review help make selection accountable. Updating a list without updating procurement contracts or clinical guidance can produce a nominal change with little effect on care. Conversely, a tightly restricted list that is not revised may fail to accommodate improved treatments. The operational challenge is to maintain a stable, manageable selection while allowing justified changes as evidence, prices, and population needs evolve.
Prices, financing, and intellectual property
The price of a medicine reflects several interacting factors: manufacturing costs, the number of suppliers, purchasing volume, distribution expenses, taxes or mark-ups, market structure, and legal exclusivities. Essential status does not itself set a price. Nor does it mean that a medicine is inexpensive everywhere. The same active ingredient can have widely different acquisition and retail prices across countries and purchasing channels.
Competition among suppliers of generic medicines can lower prices after applicable exclusivities permit market entry. A generic product contains the same active ingredient as its reference medicine and must meet relevant regulatory requirements for quality and equivalence. For many conventional medicines, demonstration of bioavailability and bioequivalence supports this assessment. Complex biological medicines require a different comparability framework: a biosimilar is evaluated for high similarity to an authorized reference biological product, without clinically meaningful differences in relevant clinical performance. Neither generic nor biosimilar status removes the need for effective regulation.
Intellectual property affects access where patents or other protections restrict competing supply. The World Trade Organization’s Agreement on Trade-Related Aspects of Intellectual Property Rights establishes international obligations while containing flexibilities. The 2001 Doha Declaration on the TRIPS Agreement and Public Health affirmed that the agreement should be interpreted and implemented in a manner supportive of members’ right to protect public health and promote access to medicines for all. Mechanisms such as compulsory licensing and voluntary licensing operate within specific legal conditions; essential medicines listing does not itself override a patent.
Purchasers also use negotiations, pooled procurement, and competitive tenders. Combining demand can increase bargaining power and make orders more predictable for suppliers. Tiered pricing may offer different prices to different markets, although the resulting affordability depends on eligibility, contractual terms, and local financing. A low quoted price is not necessarily the lowest cost of treatment if the product requires expensive administration, substantial wastage, or additional monitoring.
Budget impact remains distinct from a medicine’s price and cost-effectiveness. A modestly priced treatment used by millions of people may require a larger annual appropriation than an expensive treatment for a small population. Funding decisions must also account for the services that make treatment effective, including diagnostic testing and trained staff. From the household perspective, affordability depends on income, insurance coverage, user charges, and indirect costs such as transport. These differences explain why a product may be affordable to a national purchasing agency but remain inaccessible to patients. Price policy, benefit design, and supply reliability therefore address separate, complementary parts of access.
Procurement, quality assurance, and distribution
Selection creates a defined purchasing target, but availability depends on the supply chain. Quantification estimates which medicines will be needed, in what amounts, and at which facilities. Common methods use previous consumption, expected service activity, or disease and treatment data. Each has limitations. Consumption records underestimate need when earlier stockouts prevented dispensing, while disease-based estimates can overstate short-term demand if diagnostic coverage or service capacity is low.
Procurement then translates estimated need into contracts and deliveries. Tender specifications must describe the required product, formulation, strength, packaging, quality standards, and delivery conditions. Assessment of suppliers involves more than comparing unit prices. Manufacturing quality, regulatory compliance, delivery reliability, remaining shelf life, and capacity to replace rejected shipments can substantially affect value. Excessive dependence on a single supplier may reduce resilience even where it initially secures a low price.
Good manufacturing practice and effective regulatory oversight help ensure that products consistently meet quality requirements. WHO prequalification provides an assessment mechanism for specified categories of priority medical products and is used by many international procurement agencies. It does not cover every medicine on the Model List, and essential status is not a certificate of product quality. Authorization, manufacturing inspection, laboratory testing, and post-market surveillance remain separate functions.
Storage and distribution must preserve quality until use. Heat, humidity, light, physical damage, and inappropriate transport can degrade products or packaging. Some medicines require a cold chain, with temperature-controlled storage and transport throughout distribution. Others tolerate ordinary storage conditions but still require protection from excessive heat or moisture. Inventory systems commonly use first-expiry, first-out practices to reduce wastage. Appropriate buffer stocks can help absorb delayed deliveries, although excessive stock increases the risk of expiry and ties up funds.
Shortages can arise from manufacturing failures, shortages of ingredients, inaccurate forecasts, delayed payment, transport disruption, or sudden changes in demand. A stockout at a central warehouse and a stockout at a local clinic are different events and require different responses. Reliable logistics information distinguishes stock on hand, stock in transit, consumption, losses, and expiry dates. Substandard products, which fail quality specifications, must also be distinguished from falsified products, whose identity, composition, or source is deliberately misrepresented. Both threaten treatment outcomes and patient safety, but the regulatory and investigative problems differ. A medicine is meaningfully available only when the right, quality-assured product reaches the place where it can be appropriately used.
Appropriate use and antimicrobial stewardship
Making medicines available does not ensure that they are used effectively. Appropriate use depends on a sound diagnosis, an evidence-based treatment choice, suitable dose and duration, appropriate dispensing, and follow-up when required. It also depends on whether patients receive understandable information and can follow the treatment plan. Essential medicines policy therefore includes prescribing and dispensing practices as well as selection and supply.
Standard treatment guidelines can connect a clinical problem to medicines on the relevant list. Their usefulness depends on alignment with actual stocks, local disease patterns, and the capabilities of the service. Training, audit and feedback, prescription review, and drug and therapeutics committees can help identify avoidable variation. Examples include duplicate medicines from the same therapeutic class, unnecessary injections, and prescribing several products when fewer provide equivalent benefit. Such practices can increase costs and adverse effects without improving outcomes.
Antibiotics present a particularly important collective problem because their use can select for resistant organisms. Antimicrobial resistance reduces the effectiveness of treatment and can affect people beyond the individual receiving a medicine. WHO’s 2017 AWaRe classification divides antibiotics into Access, Watch, and Reserve groups. Access antibiotics generally have activity against common susceptible pathogens and comparatively lower resistance potential. Watch antibiotics have higher resistance potential and are priority targets for monitoring. Reserve antibiotics are intended for selected situations involving suspected or confirmed infections due to multidrug-resistant organisms.
AWaRe is not a simple ranking in which one group is always clinically preferable. The appropriate medicine depends on the infection, likely or identified organism, susceptibility, severity, and patient factors. An Access antibiotic may be ineffective against a resistant infection, while a Watch antibiotic may be the appropriate initial choice for a particular severe condition. Antimicrobial stewardship links these distinctions to diagnostic services, treatment guidelines, prescribing review, and resistance surveillance. Restricted access to an effective antibiotic can be as consequential as unnecessary use of one.
Responsible use also extends to medicines whose access is constrained by controlled-substance regulation. Opioids illustrate the need to address diversion and harmful use without preventing legitimate treatment of severe pain. Post-market safety systems, including pharmacovigilance, collect and assess information on suspected adverse reactions and other medicine-related problems. New safety findings can lead to revised warnings, restrictions, formulation changes, or reconsideration of a listing. Essentiality thus remains conditional on the balance of benefits and harms for specified uses; it is not an exemption from continuing safety assessment.
Measuring access and identifying inequities
Access is multidimensional. A medicine must be selected for the relevant need, physically available, of assured quality, financially accessible, and usable within the surrounding health service. A product found in a warehouse may not be accessible to a patient if a prescription requires an unavailable specialist or if the accompanying test cannot be performed. Measurement therefore needs to distinguish the existence of a product from effective access to treatment.
Availability surveys commonly record whether specified medicines are present at selected facilities on the survey day. These surveys provide a useful snapshot but may miss repeated or seasonal shortages. Longitudinal measures, such as the number of stockout days over a year, capture continuity more directly. Results also depend on the basket of medicines surveyed, whether public and private outlets are included, and how facilities are sampled. Comparing countries without accounting for these methods can be misleading.
The WHO/Health Action International methodology has been widely used to study medicine prices, availability, affordability, and price components. Prices may be expressed relative to an international reference price, while affordability has often been expressed as the number of days’ wages required for a treatment by the lowest-paid unskilled government worker. These indicators make comparisons possible but do not represent every household’s circumstances. Informal workers, unemployed people, and households purchasing several treatments may face burdens not captured by a single wage-based measure.
The Sustainable Development Goals include indicator 3.b.3, concerning the proportion of health facilities with a core set of relevant essential medicines available and affordable on a sustainable basis. Its formulation recognizes that physical availability and affordability must be considered together. Other measures examine insurance coverage, out-of-pocket expenditure, prescription filling, or continuity of treatment. None is sufficient alone: an insurance scheme can formally cover a medicine that is repeatedly out of stock, while a private pharmacy can stock it at a price that many households cannot pay.
Health equity analysis disaggregates these findings by geography, income, age, sex, disability, and other relevant characteristics. Rural facilities may experience different distribution constraints from urban referral hospitals. Children may lack usable formulations even when adult products are present. People requiring long-term treatment face a continuity problem that a one-time availability survey cannot capture. The interpretation of access data consequently depends on the clinical need and treatment pathway being measured, as well as on broader social determinants of health that influence the ability to seek and obtain care.
Changing treatment needs and limits of the framework
The range of conditions addressed by essential medicines policy has expanded alongside the growing burden of noncommunicable diseases. Continuous treatment for cardiovascular disease, chronic respiratory illness, diabetes, and mental disorders requires a different supply pattern from a short course for an acute infection. Patients with several conditions may need multiple medicines, monitoring, and coordinated follow-up. A list organized by therapeutic category does not by itself resolve interactions, cumulative treatment burden, or fragmented care.
The relationship between medicines and diagnostic infrastructure has also become more prominent. Some treatments depend on confirming an infection, measuring organ function, or identifying a molecular feature of a tumor. A listed cancer medicine may have substantial benefit only for patients with a particular biomarker. WHO published its first Model List of Essential In Vitro Diagnostics in 2018, providing a complementary selection framework. The medicine and diagnostic lists remain distinct, but both address the practical conditions required for effective care.
High-cost treatments create difficult priority-setting questions. Advances in cancer treatment and other specialist fields can produce meaningful benefits, but evidence may be limited by short follow-up, selected trial populations, or uncertainty about comparisons with existing care. A favorable result on disease progression does not always establish longer survival or improved quality of life. Selection committees must distinguish therapeutic advance from novelty and determine whether the necessary services can be delivered. Listing can identify a priority and strengthen the case for access measures, but it cannot create manufacturing capacity or a financing mechanism.
Supply resilience introduces another tension. Purchasing from the least expensive qualified supplier can conserve funds, while concentrating production or contracts may increase vulnerability to disruption. Maintaining alternative suppliers, reserve stocks, or additional production capacity carries costs that may not appear in a simple unit-price comparison. Emergencies, including the COVID-19 pandemic, demonstrated how simultaneous increases in demand and interruptions to transport and manufacturing can affect access even to long-established products. Emergency purchasing also heightens the importance of quality assurance.
Finally, the concept has defined boundaries. An essential medicines list does not describe every potentially beneficial treatment, and absence from the WHO Model List is not proof that a medicine is ineffective. A treatment may not have been assessed, may have a narrow indication, or may not yet meet the evidentiary threshold for listing. Conversely, inclusion does not establish suitability for every setting or patient. The framework operates through explicit selection for priority needs; individual clinical decisions, regulatory authorization, service design, and financing remain necessary and distinct responsibilities.